Characteristics | BMS group | Control group | P |
---|---|---|---|
n(%) | n(%) | ||
No | 121 | 121 | Â |
Age,(mean, s.d) | 57.21(10.63) | 55.73(10.45) | 0.276 |
Range | 28–75 | 20–72 |  |
< 60 | 72(59.50%) | 81(66.90%) | 0.230 |
≥ 60 | 49(40.50%) | 40(33.10%) |  |
KPS | Â | Â | Â |
70 | 0 | 0 | 0.511 |
80 | 3(2.50%) | 5(4.10%) | Â |
90 | 48(39.70%) | 54(44.60%) | Â |
100 | 70(57.90%) | 62(51.20%) | Â |
FIGO stage | Â | Â | Â |
IB3-II | 74(61.20%) | 68(56.20%) | 0.433 |
III-IVA | 47(38.80%) | 53(43.80%) | Â |
in detail | Â | Â | Â |
IB3 | 38(31.40%) | 26(21.50%) | 0.210 |
IIA2 | 15(12.40%) | 10(8.30%) | Â |
IIB | 21(17.40%) | 32(26.40%) | Â |
IIIA | 1(0.80%) | 3(2.50%) | Â |
IIIB | 3(2.50%) | 4(3.30%) | Â |
IIIC1 | 26(21.50%) | 29(24.00%) | Â |
IIIC2 | 11(9.10%) | 15(12.40%) | Â |
IVA | 6(5.00%) | 2(1.70%) | Â |
Histologic type | Â | Â | Â |
Squamous cell carcinoma | 103(85.10%) | 105(86.80%) | 0.870 |
Adenocarcinoma | 13(10.70%) | 13(10.70%) | Â |
Adenosquamous carcinoma | 5(4.10%) | 3(2.50%) | Â |
Concurrent chemotherapy cycles received | Â | Â | Â |
4 | 9(7.40%) | 7(5.80%) | 0.719 |
5 | 33(27.30%) | 38(31.40%) | Â |
6 | 79(65.30%) | 76(62.80%) | Â |
Adjuvant chemotherapy cycles received | Â | Â | Â |
0 | 69(57.00%) | 63(52.10%) | 0.719 |
2 | 5(4.10%) | 8(6.60%) | Â |
3 | 1(0.80%) | 2(1.70%) | Â |
4 | 46(38.00%) | 48(39.70%) | Â |
EBRT dose | Â | Â | Â |
45Â Gy/25f | 42(34.70%) | 45(37.20%) | 0.922 |
50Â Gy/25f | 53(43.80%) | 51(42.10%) | Â |
50.4Â Gy/28f | 26(21.50%) | 25(20.70%) | Â |
SIB prescribed | Â | Â | Â |
50Â Gy/25f | 14(11.60%) | 21(17.40%) | 0.441 |
61.6Â Gy/28f | 26(21.50%) | 24(19.80%) | Â |
No | 81(66.90%) | 76(62.80%) | Â |
ICBT dose | Â | Â | Â |
30Â Gy/5f | 76(62.80%) | 72(59.50%) | 0.598 |
28Â Gy/4f | 45(37.20%) | 49(40.50%) | Â |
Baseline blood count test (mean, s.d) | Â | Â | |
WBC, *10^9/L | 6.39(3.74) | 6.32(3.76) | 0.887 |
ANC, *10^9/L | 4.60(3.26) | 4.43(3.51) | 0.704 |
HGB, g/L | 120.60(15.08) | 118.10(14.80) | 0.194 |
PLT, *10^9/L | 214.03(78.92) | 208.98(82.23) | 0.626 |
LYM,*10^9/L | 1.37(0.59) | 1.41(0.61) | 0.663 |
Baseline HT(excluding lymphopenia) | Â | Â | Â |
Grade 0 | 53(43.80%) | 47(38.8%) | 0.112 |
Grade 1 | 61(50.4%) | 54(44.6%) | Â |
Grade 2 | 7(5.8%) | 20(16.5%) | Â |
Grade 3 | 0 | 0 | Â |
Grade 4 | 0 | 0 | Â |